Hubei Goto Biopharm Co.,Ltd. (300966.SZ)
CNY 16.06
(1.58%)
CNY 16.06
(1.58%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 566.39 Million CNY | -6.31% |
| 2022 | 604.57 Million CNY | 2.32% |
| 2021 | 590.88 Million CNY | 26.23% |
| 2020 | 468.11 Million CNY | 0.71% |
| 2019 | 464.8 Million CNY | 6.29% |
| 2018 | 437.3 Million CNY | 31.05% |
| 2017 | 333.69 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 131.56 Million CNY | 18.26% |
| 2024 Q1 | 122.22 Million CNY | -32.61% |
| 2024 Q2 | 111.25 Million CNY | -8.98% |
| 2023 FY | 566.39 Million CNY | -6.31% |
| 2023 Q3 | 117.21 Million CNY | -21.01% |
| 2023 Q4 | 181.36 Million CNY | 54.72% |
| 2023 Q1 | 119.42 Million CNY | -24.29% |
| 2023 Q2 | 148.39 Million CNY | 24.26% |
| 2022 Q2 | 147.89 Million CNY | 22.79% |
| 2022 Q1 | 120.45 Million CNY | -16.89% |
| 2022 FY | 604.57 Million CNY | 2.32% |
| 2022 Q4 | 157.74 Million CNY | -11.61% |
| 2022 Q3 | 178.47 Million CNY | 20.68% |
| 2021 Q1 | 141.82 Million CNY | -4.57% |
| 2021 FY | 590.88 Million CNY | 26.23% |
| 2021 Q4 | 144.93 Million CNY | 1.16% |
| 2021 Q3 | 143.27 Million CNY | -10.93% |
| 2021 Q2 | 160.85 Million CNY | 13.41% |
| 2020 Q4 | 148.62 Million CNY | 26.57% |
| 2020 Q3 | 117.42 Million CNY | -28.89% |
| 2020 Q2 | 165.13 Million CNY | 347.18% |
| 2020 Q1 | 36.92 Million CNY | -66.91% |
| 2020 FY | 468.11 Million CNY | 0.71% |
| 2019 Q4 | 111.59 Million CNY | 0.0% |
| 2019 FY | 464.8 Million CNY | 6.29% |
| 2018 FY | 437.3 Million CNY | 31.05% |
| 2017 FY | 333.69 Million CNY | 0.0% |